CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States
305-420-3200
http://www.catalystpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder, Chairman, Pres & CEO856.3kN/A1947
Dr. Steven R. MillerCOO & Chief Scientific Officer608.92kN/A1962
Dr. Gary IngenitoChief Medical Officer & Head of Regulatory Affairs620.38kN/A1956
Ms. Alicia GrandeVP, Treasurer & CFON/AN/A1971
Mr. Brian ElsberndChief Legal & Compliance OfficerN/AN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.